// App-Quantinova.ai

: Six months’ treatment with MIV-711, a novel Cathepsin K inhibitor induces osteoarthritis structure modification: results from a randomized double-blind placebo-controlled phase IIA trial

Researchers

Presenter

  • P.G. Conaghan

Principal Investigators

  • M.A. Bowes

  • S.R. Kingsbury

  • A. Brett

  • G. Guillard

  • K. Tunblad

  • B. Rizoska

  • T. Larsson

  • . Holmgren

  • A. Manninen

  • K. Ghlin

  • W. Heber

  • P. Graham

  • . Jansson

  • C. Wadell

  • R. Bethell

  • J. hd

Medical Centers

  • University of Leeds, Leeds, United Kingdom

  • Imorphics, Manchester, United Kingdom

  • Medivir AB, Huddinge, Sweden

  • PAREXEL, Baltimore, MD, USA

Locations

  • United Kingdom

  • Sweden

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • Osteoarthritis

Biomarkers

  • Cathepsin X

  • Nutritional risk screening

  • Albumin/creatinine

Drug/Treatment

  • MIV711

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved